The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 327-337

  Anfossi, Giovanni ^a   Russo, Isabella ^a   Bonomo, Katia ^a   Trovati, Mariella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

References

Indexed keywords

ADIPOCYTOKINE; ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METFORMIN; MIGRATION INHIBITION FACTOR; SULFONYLUREA DERIVATIVE; TRANILAST; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL PAIN; ANOREXIA; ANTIHYPERGLYCEMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC PATIENT; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; FOOD DRUG INTERACTION; GLYCEMIC CONTROL; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC ACTION; INFLAMMATION; LACTIC ACIDOSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MICROANGIOPATHY; MOLECULAR MECHANICS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; RESTENOSIS; SINGLE DRUG DOSE; TASTE DISORDER; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 77952941576     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112359     Document Type: Article

References (154)

1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-90.
2. Baumgartl HJ, Standl E. The atherosclerotic process and its exacerbation by diabetes. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl 2): S487-92.
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
4. Strojek K. Features of macrovascular complications in type 2 diabetic patients. Acta Diabetol 2003; 40 (Suppl 2): S334-7.
5. Laight DW, Carrier MJ, Anggård EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 1999; 15: 274-82.
6. Trovati M, Anfossi G. Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus. Curr Diabetes Rep 2002; 2: 316-22.
7. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
9. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
10. Home PD. Impact of the UKPDS-an overview. Diabetes Med 2008; 25 (Suppl 2): 2-8.
11. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686-95.
12. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800-9.
13. Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007; 293: E337-46.
14. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008; 93: 578-83.
15. Piga R, Naito Y, Kokura S, Handa O, Yoshikawa T. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007; 193: 328-34.
16. Cohen RA. Role of nitric oxide in diabetic complications. Am J Ther 2005; 12: 499-502.
17. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107: 853-60.
18. Vikramadithyan RK, Hu Y, Noh HL, et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005; 115: 2434-43.
19. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1137-43.
20. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-97.
21. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
22. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005; 183: 259-67.
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
24. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55: 498-510.
25. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diabetes Rep 2007; 7: 242-8.
26. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 487-96.
27. Manduteanu I, Voinea M, Serban G, Simionescu M. High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothelium 1999; 6: 315-24.
28. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1542-8.
29. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
30. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: II27-III32.
31. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006; 186: 240-59.
32. Muniyappa R, Quon MJ. Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr Metab Care 2007; 10: 523-30.
33. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
34. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
35. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-8.
36. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
37. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
38. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997; 46: 1497-503.
39. Mäkimattila S, Liu ML, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 1999; 22: 973-81.
40. Rodríguez-Mañas L, López-Dóriga P, Petidier R, et al. Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes. J Hypertens 2003; 21: 1137-43.
41. Abe H, Yamada N, Kamata K, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998; 101: 1784-8.
42. Lavrencic A, Salobir BG, Keber I. Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 2000; 20: 551-5.
43. Sung BH, Izzo JL, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 1999; 34: 83-8.
44. Verma S, Yao L, Dumont A, McNeill J. Metformin treatment corrects vascular insulin resistance in hypertension. J Hypertens 2000; 18: 1445-50.
45. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37; 1344-50.
46. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
47. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-62.
48. Adiels M, Olofsson SO, Taskinen MR, Borén J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006; 17: 238-46.
49. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004; 109: 1022-8.
50. Ting HJ, Stice JP, Schaff UY, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 2007; 100: 381-90.
51. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006; 35: 491-510.
52. Schneider DJ. Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005; 16: 473-6.
53. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005; 5: 323-32.
54. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
55. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diab Res Clin Pract 2000; 50: 1-16.
56. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-85.
57. Anfossi G, Russo I, Trovati M. Platelet resistance to the antiaggregating agents in the insulin resistant states. Curr Diabetes Rev 2006; 2:409-30.
58. Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997: 29: 631-5.
59. Cusi K, Defronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131.
60. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
61. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30: 359-71.
62. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110.
63. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415-22.
64. Bailey CJ. Metformin - an update. Gen Pharmacol 1993; 24: 1299-309.
65. Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998; 21: 1301-5.
66. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632-40.
67. Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of metformin on intestinal glucose absorption. J Pharm Pharmacol 1991; 43: 120-1.
68. Bailey CJ. Metformin and intestinal glucose handling. Diabetes Metab Rev 1995; 11 (Suppl 1): S23-32.
69. Ikeda T, Iwata K, Murakami H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol 2000; 59: 887-90.
70. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia 2008; 51: 1552-3.
71. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-4.
72. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
73. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999; 58 (Suppl 1): 31-9.
74. Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR. Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 1996; 137: 113-21.
75. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13: 696-704.
76. Ferner RE, Rawlins MD, Alberti KG. Impaired beta-cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes. QJM 1988; 66: 137-46.
77. Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabetes Med 2005; 22: 654-7.
78. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72.
79. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-45.
80. Ahrén B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008; 4: 383-94.
81. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999; 20: 489-503.
82. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulinresistant human HepG2 cells. J Biol Chem 2004; 279: 47898-905.
83. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-81.
84. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74.
85. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003; 546: 113-20.
86. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008; 9: 478-92.
87. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated Protein Kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-32.
88. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008; 117: 952-62.
89. Hardie DG. The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 2004; 117: 5479-87.
90. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
91. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
92. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
93. Kao J, Tobis J, McClelland RL, et al. Investigators in the Prevention of Restenosis With Tranilast and Its Outcomes Trial. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004; 93: 1347-50.
94. Evans JM, Ogston SA, Emslie-Smith MA, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 2006; 49: 930-6.
95. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8.
96. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-80.
97. Matsumoto K, Sera Y, Abe Y, Tominaga T, Yeki Y, Miyake S. Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes. Diabetes Res Clin Pract 2004; 64: 225-8.
98. Meaney E, Vela A, Samaniego V, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008; 35: 895-903.
99. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4: 89-102.
100. Romualdi D, Costantini B, Selvaggi L, et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. Hum Reprod 2008; 23: 2127-33.
101. de Aguiar LG, Bahia LR, Villela N, et al. Metformin improves endothelial vascular reactivity in first degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 2006; 29: 1083-9.
102. Vitale C, Mercuro G, Cornoldi A, Fini M, Volterrani M, Rosano GM. Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 2005; 258: 250-6.
103. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256: 1-14.
104. Grant PJ. Beneficial effects of metformini on haemostasis and vascular function in man. Diabetes Metab 2003; 29: 6S44-52.
105. Chakrabarti R, Hocking ED, Fearnley GR. Fibrinolytic effect of metformin in coronary artery disease. Lancet 1965; II: 256-9.
106. Hocking ED, Chakrabarti R, Evans J, Fearnley GR. Effects of biguanides and atromid on fibrinolysis. J Atheroscler Res 1967; 7: 121-30.
107. Standeven KF, Ariëns RA, Whitaker P, Ashcroft AE, Weisel JW, Grant PJ. The effect of dimethyl biguanide on thrombin activity FXIII activation, fibrin polymerization and fibrin clot formation. Diabetes 2002; 51: 189-97.
108. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activation inhibitor activity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemostasis 1987; 57: 326-8.
109. Grant PJ, Strickl MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991; 8: 361-5.
110. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-9.
111. He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor- 1 production in human adipose tissue. Horm Metab Res 2003; 35: 18-23.
112. Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus. Horm Metab Res 1985; 12: 120-2.
113. Gregorio F, Ambrosi F, Manfrini S. Poorly controlled elderly type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med 1999; 16: 1016-24.
114. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
115. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS. The role of C-Reactive Protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 2008; 6: 258-70.
116. Isoda K, Young JL, Zirlik A, et al. Metformin inhibits proinflammatory responses and Nuclear Factor-{kappa}B in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26: 611-7.
117. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 1282-4.
118. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine 2005; 20: 215-8.
119. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649-54.
120. Orio F, Manguso F, Di Biase S, et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007; 157: 69-73.
121. Lund SS, Tarnow L, Stehouwer CD, et al. Impact of metformin vs. repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 631-41.
122. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004; 89: 3943-8.
123. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004; 89: 5043-7.
124. Miina K, Öhman MK, Andrew P, et al. Visceral adipose tissue and atherosclerosis. Curr Vasc Pharmacol 2009; 7: 169-79.
125. Pfeiffer AF. Adipose tissue and diabetes therapy: do we hit the target? Horm Metab Res 2007; 39: 734-8.
126. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-13.
127. Klein J, Westphal S, Kraus D, et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes. J Endocrinol 2004; 183: 299-307.
128. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457-61.
129. Glueck CJ, Fontaine RN, Wang P, et al. Metformin reduces weight, centropedal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50: 856-61.
130. Fruehwald-Schultes B, Oltmanns KM, Toschek B, et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 2002; 51: 531-6.
131. Jung HS, Youn BS, Cho YM, et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54: 314-20.
132. Fujita H, Fujishima H, Koshimura J, et al. Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice. Endocr J 2005; 52: 427-33.
133. Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003; 52: 667-74.
134. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29: 6S95-103.
135. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets 2005; 6: 453-74.
136. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58: 1765-73.
137. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005; 54: 2179-87.
138. Batandier C, Guigas B, Detaille D, et al. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 2006; 38: 33-42.
139. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Thérond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005; 54: 829-34.
140. Gallo A, Ceolotto G, Pinton P, et al. Metformin prevents glucose-induced protein kinase C-beta2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 2005; 54: 1123-31.
141. Mahrouf M, Ouslimani N, Peynet J, et al. Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C. Biochem Pharmacol 2006; 72: 176-83.
142. Gargiulo P, Caccese D, Pignatelli P, et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 2002; 18: 156-9.
143. Formoso G, De Filippis EA, Michetti N, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008; 24: 231-7.
144. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci 2008; 114: 251-6.
145. Zou M-H, Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008; 35: 535-45.
146. Hardie DG. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 2008; 582: 81-9.
147. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-25.
148. Bosi E. Metformin - the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009; 11 (Suppl 2): 3-8.
149. Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443: 285-9.
150. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor {kappa}B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006; 47: 1183-8.
151. Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003; 29: 6S71-6.
152. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 2008; 22: 215-24.
153. Wiernsperger NF. 50 years later: is metformin a vascular drug with antidiabetic properties? Br J DiabetesVasc Dis 2007; 7: 204-10.
154. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60.